Amgen Inc. (AMGN): analysis and signal as of September 4, 2026

Published on September 4, 2026 at 07:40 · Updated on September 4, 2026 at 07:40 · by Aurélien Ambert, QDNA

Exchange : NASDAQ · Sector : Healthcare

In short

WEAK signal on Amgen, vote 3/3, due to a share price already above consensus and the 200-session moving average, without sector support. The upside potential rests essentially on the MariTide phase 3 verdict and on a pause in American tariff policy.

Current signal: weak (vote 3/3)
Deterministic score: +4.0 → signal expected by the scale : moderate (September 10, 2026)
Layers: fundamentals : positive, price : neutral, risks : neutral

Triggered rules

Rule	Weight
favors (GARP) a stock whose PEG is below 1, growth not yet paid for	+1.5
favors robust fundamental health (high Piotroski F-Score)	+1.5
penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE	-1.0
favors a "fast grower" profile, high and durable earnings growth (> 20 %), to be cross-checked against the PEG	+1.0
moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation)	+0.5
moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger	+0.5

Thesis

Amgen displays solid execution, with six growth drivers at +26 % covering nearly 70 % of product sales and a raised 2026 guidance. The macroeconomic context favours defensive healthcare names. However, the market has already priced in this execution, which places the stock above consensus and the 200-session moving average, with a rising PER premium and a reference sector pulling back.

Bull case

Fundamentals deliver dated figures, with Q2 2026 revenues at 10.1 B USD (+10 %), 22 products growing at double digits and guidance raised from 38.2 to 39.4 B USD with a non-GAAP EPS of 22.30 to 23.50 USD. Free cash flow improves, the forward PER of 18.5 remains supportable and short interest recedes by 9.3 %. The rally is driven by institutional intraday flows.

Bear case

The price has already absorbed execution, with 444.12 USD against a mean target of 386.68 USD across 39 analysts, i.e. A downside of -12.7 %, an overextension of +12.8 % on the MM50 and +25.6 % on the MM200. The accounting PER sits above its average, while American tariff policy weighs on net prices. MariTide has delivered no phase 3 data and the reference sector pulls back by around 7 % in 2026, which concentrates the rally on a single stock.

Scenarios

Bullish scenario at 25 %, with a 510 to 530 USD target on positive MariTide phase 3 then catch-up of analyst revisions. Central scenario at 50 %, consolidation between 390 and 420 USD around consensus and the MM50, with a time to absorb the premium. Bearish scenario at 25 %, maximum loss of -22 % (345 to 360 USD zone) on clinical failure, tariff shock or guidance disappointment.

Risks

The main risk centres on MariTide, whose absence of phase 3 data exposes the stock to clinical failure. American tariff policy, through MFN, Medicare and Section 232 models, can compress net prices. The share price overextension of 25.6 % above the MM200 and the absence of sector support raise the risk of consolidation. Lastly, the accounting PER above its average leaves little margin in the event of guidance disappointment.

Market positioning (short sellers)

Short interest / shares outstanding: 2.41 %
Days to cover: 5.62
Settlement date: 2026-08-31
Source: FINRA (disseminated on 2026-09-12)

Market information published by FINRA (consolidated short interest, all venues), no directional comment.

Signal history (last 12 months)

Date	Signal	New fact
September 4, 2026	weak (3/3)	Unchanged. No prior verdict in memory, no new dated fact since the 03/09/2026 session. Personal analysis, not advice.

Frequently asked questions

What does a WEAK signal on Amgen mean?

A WEAK signal reflects a score insufficient to act decisively, despite solid fundamentals. Here, the share price already exceeds consensus by 12.7 % and the MM200 by 25.6 %, without sector support, which limits immediate upside. The upside potential depends on the MariTide phase 3 verdict.

Why is the share price above consensus?

The price at 444.12 USD exceeds the mean target of 386.68 USD across 39 analysts, i.e. A downside of -12.7 %. The market has absorbed operational execution, with 22 products growing at double digits, and anticipates a positive phase 3 verdict for MariTide. This anticipation concentrates the rally on a single clinical event.

What is the main growth driver?

Six growth drivers post +26 % and cover nearly 70 % of product sales. Q2 2026 revenues reach 10.1 B USD, up 10 %, and 2026 guidance has been raised to 38.2 to 39.4 B USD. Free cash flow improves, with 1.5 B USD in Q1 versus 1.0 B USD a year earlier.

What is the impact of American tariff policy?

American tariff policy, through MFN, Medicare and Section 232 models, weighs on net prices of pharmaceutical products. This pressure represents a structural risk for Amgen's margins. Combined with the absence of sector support, it raises the risk of share price consolidation.

What should be monitored in the coming months?

The MariTide phase 3 verdict is the central event, with significant upside or downside potential. A pullback towards the consolidation zone between 390 and 420 USD would provide a technical observation point. Lastly, the evolution of the reference sector, pulling back by around 7 % in 2026, remains a key context indicator.

Sources

The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.

August 5, 2026 — 10-Q (SEC · 10-Q)
August 4, 2026 — 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits (SEC · 8-K)
July 31, 2026 — 1.05 Material Cybersecurity Incidents (SEC · 8-K)
May 20, 2026 — 5.07 Submission of Matters to a Vote of Security Holders (SEC · 8-K)
May 19, 2026 — 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers (SEC · 8-K)

Automated AI analysis: limitations and transparency

This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
Tool and analysis: QDNA, Aurélien Ambert.
Analysis (arbitration) completed on September 4, 2026; this page was completed on September 4, 2026 at 07:40 (UTC).
Interests: no position in the stock analysed (AMGN) is recorded in the data consulted on September 12, 2026 (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
Methodology: analysis chain, score formula and scale described on the public methodology page.
Analysis horizon: 2035.